BDNF levels in serum and CSF are associated with clinicoradiological characteristics of aggressive disease in MS patients
Journal of Neurology · 2025
DOI: 10.1007/s00415-024-12875-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurology, 2025. Verfasst von Michelle Maiworm und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital Frankfurt, Frankfurt Am Main, Germany. Maiworm@med.uni-frankfurt.de. Hauptthemen laut MEDLINE: Brain-Derived Neurotrophic Factor, Multiple Sclerosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi Genzyme, Universitätsklinikum Frankfurt.
Abstract (Originalsprache)
Background
BDNF has increasingly gained attention as a key molecule controlling remyelination with a prominent role in neuroplasticity and neuroprotection. Still, it remains unclear how BDNF relates to clinicoradiological characteristics particularly at the early stage of the disease where precise prognosis for the further MS course is crucial.
Methods
BDNF, NfL and GFAP concentrations in serum and CSF were assessed in 106 treatment naïve patients with MS (pwMS) as well as 73 patients with other inflammatory/non-inflammatory neurological or somatoform disorders using a single molecule array HD-1 analyser. PwMS were evaluated for highly active profiles by applying the aggressive disease course criteria proposed by ECTRIMS. Serum/CSF values were logarithmically transformed and compared across groups using one-way ANOVA, while correlations were calculated using Pearson’s correlations. ROC analysis and AUC comparisons for diagnostic performance of the three biomarkers were computed in an explorative analysis.
Results
Serum BDNF (sBDNF) concentrations were higher in treatment naïve pwMS with disease onset after the age of 40 years ( p = 0.029), in pwMS with ≥2 gadolinium-enhancing lesions ( p = 0.009) and with motor, cerebellar, cognitive or sphincter symptoms at onset ( p = 0.036). BDNF correlated positively with NfL ( r = 0.198, p = 0.014) and GFAP ( r = 0.253, p = 0.002) in serum, but not in CSF. Neurological patients with an acute inflammatory relapse showed significantly higher sBDNF levels ( p = 0.03) compared to somatoform controls, while patients without acute relapse did not differ from somatoform controls ( p = 0.4). Better diagnostic performance was found for sBDNF than sNfL and sGFAP in differentiating between patients with vs. without 2 or more gadolinium-enhancing lesions ( p < 0.05) and for sBDNF as compared to sNfL for separating patients with disease onset after vs. before age of 40 years.
Conclusion
In pwMS, BDNF serum levels differ depending on disease-related characteristics, suggesting that not only inflammatory activity but also remyelination capacities may vary with disease severity. BDNF is increased when other biomarkers of neuroaxonal damage and neurodegeneration, such as NfL and GFAP, are elevated, possibly as a compensatory mechanism, and reflect possibly further pathophysiological aspects in MS beyond NfL and GFAP, probably including an apoptotic role for BDNF in neuroinflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University Hospital Frankfurt, Frankfurt Am Main, Germany. Maiworm@med.uni-frankfurt.de.
- Department of Neurology, University Hospital Frankfurt, Frankfurt Am Main, Germany.
- Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (Rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germa…
- Practice for Neurology and Psychiatry Eltville, Eltville Am Rhein, Germany.
- Institute of Neuroradiology, University Hospital Frankfurt, Frankfurt Am Main, Germany.
- Department of Radiology, Sankt Katharinen Hospital, Frankfurt Am Main, Germany.
Förderung
- Sanofi Genzyme
- Universitätsklinikum Frankfurt
Zitieren
APA
Maiworm, M., Koerbel, K., Anschütz, V., Jakob, J., Schaller-Paule, M. A., Schäfer, J. H., Friedauer, L., Wenger, K. J., Hoelter, M. C., Steffen, F., Bittner, S., Foerch, C., & Yalachkov, Y. (2025). BDNF levels in serum and CSF are associated with clinicoradiological characteristics of aggressive disease in MS patients. Journal of Neurology. https://doi.org/10.1007/s00415-024-12875-3
Vancouver
Maiworm M, Koerbel K, Anschütz V, Jakob J, Schaller-Paule MA, Schäfer JH, et al. BDNF levels in serum and CSF are associated with clinicoradiological characteristics of aggressive disease in MS patients. Journal of Neurology. 2025. doi:10.1007/s00415-024-12875-3
BibTeX
@article{Maiworm2025,
author = {Maiworm, Michelle and Koerbel, Kimberly and Anschütz, Victoria and Jakob, Jasmin and Schaller-Paule, Martin A and Schäfer, Jan Hendrik and Friedauer, Lucie and Wenger, Katharina J and Hoelter, Maya C and Steffen, Falk and Bittner, Stefan and Foerch, Christian and Yalachkov, Yavor},
title = {BDNF levels in serum and CSF are associated with clinicoradiological characteristics of aggressive disease in MS patients},
journal = {Journal of Neurology},
year = {2025},
doi = {10.1007/s00415-024-12875-3}
}
EUVIMED